Clinic
Brightview, LLC
Brightview, LLC was paid $501.08M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is S5000, Prescription drug, generic — 21% of everything it billed.
33Billing provider infoBRIGHTVIEW, LLC
CINCINNATI, OH 45206
CINCINNATI, OH 45206
33aNPI1659769446assigned 12/31/2014
33bProvider typeMethadone Clinic
28Total paid$501.08M
24GClaims7,922,041
24DCodes billed85
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Methadone Clinic providers in Ohio
Rank by total paid#1 of 31
Median peer was paid$2.66M
This provider vs. median188×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official NIEMAN, AMY controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 608,422 | $12.06M | |
| 2019 | 1,118,196 | $31.19M | |
| 2020 | 1,909,755 | $58.57M | |
| 2021 | 897,073 | $83.20M | |
| 2022 | 1,237,962 | $110.06M | |
| 2023 | 1,212,314 | $111.50M | |
| 2024incomplete | 938,319 | $94.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| S5000 | Prescription drug, generic | 21% | 486,179 | 308,514 | $105.11M |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 19% | 536,201 | 327,039 | $94.81M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 713,945 | 501,984 | $72.19M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.8% | 861,322 | 482,399 | $39.17M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 6.0% | 225,125 | 131,168 | $30.14M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 5.5% | 243,891 | 168,366 | $27.72M |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | 5.3% | 107,361 | 74,140 | $26.68M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 2.4% | 126,416 | 97,533 | $11.79M |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 1.9% | 140,587 | 77,193 | $9.53M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 128,314 | 101,387 | $8.53M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.4% | 154,251 | 124,232 | $7.09M |
| H0006 | Alcohol and/or drug services; case management | 1.2% | 238,656 | 169,800 | $6.24M |
73 more codes
| 90834 | Psychotherapy session, about 45 minutes | 1.2% | 93,196 | $5.80M |
| T2023 | Targeted case management; per month | 1.1% | 19,577 | $5.30M |
| 99406 | <1% | 440,882 | $3.83M | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 43,847 | $3.80M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 109,883 | $3.03M |
| 80346 | <1% | 123,454 | $2.12M | |
| T1002 | Rn services, up to 15 minutes | <1% | 58,866 | $1.97M |
| 80361 | <1% | 126,838 | $1.87M | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 74,725 | $1.72M |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13,174 | $1.70M |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | <1% | 33,829 | $1.68M |
| 99205 | Prolong outpt/office vis | <1% | 6,093 | $1.18M |
| 80356 | <1% | 126,858 | $1.04M | |
| 80373 | <1% | 126,374 | $1.04M | |
| 80365 | <1% | 126,834 | $1.03M | |
| 80354 | <1% | 126,479 | $1.03M | |
| 80348 | <1% | 124,526 | $1.03M | |
| 80355 | <1% | 123,252 | $1.02M | |
| 80366 | <1% | 123,152 | $1.01M | |
| 80360 | <1% | 123,915 | $1.01M | |
| 80353 | <1% | 123,765 | $1.00M | |
| 80358 | <1% | 121,877 | $1.00M | |
| 80324 | <1% | 122,411 | $994K | |
| 81025 | <1% | 174,574 | $983K | |
| 80363 | <1% | 65,370 | $977K | |
| 80323 | <1% | 126,299 | $967K | |
| 80349 | <1% | 116,367 | $960K | |
| H0001 | Alcohol and/or drug assessment | <1% | 16,485 | $917K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 6,491 | $879K |
| 80362 | <1% | 60,714 | $850K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 37,083 | $790K |
| 83992 | <1% | 64,886 | $769K | |
| T1003 | Lpn/lvn services, up to 15 minutes | <1% | 33,069 | $760K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 6,053 | $707K |
| 80336 | <1% | 77,017 | $640K | |
| 80334 | <1% | 77,045 | $637K | |
| 80359 | <1% | 73,388 | $599K | |
| 80371 | <1% | 70,764 | $578K | |
| 80372 | <1% | 65,211 | $544K | |
| 80367 | <1% | 65,207 | $544K | |
| 80368 | <1% | 64,841 | $541K | |
| 80369 | <1% | 64,533 | $538K | |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | <1% | 26,036 | $533K |
| 80350 | <1% | 64,704 | $532K | |
| 80321 | <1% | 41,682 | $474K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,939 | $433K |
| 82075 | <1% | 16,430 | $289K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 14,530 | $219K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 472 | $50K |
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 1,177 | $50K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,133 | $44K |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | <1% | 1,954 | $18K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 13 | $17K |
| 90785 | <1% | 621 | $7K | |
| 93000 | <1% | 449 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 325 | $6K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 60 | $5K |
| 80305 | <1% | 809 | $4K | |
| H0048 | Alcohol and/or other drug testing: collection and handling only, specimens other than blood | <1% | 265 | $4K |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 356 | $4K |
| H0012 | Alcohol and/or drug services; sub-acute detoxification (residential addiction program outpatient) | <1% | 20 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 103 | $2K |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 23 | $2K |
| 80345 | <1% | 186 | $1K | |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | <1% | 486 | $1K |
| 80332 | <1% | 123 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $1K |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | <1% | 36 | $1K |
| 90839 | <1% | 15 | $933.62 | |
| G2077 | Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code | <1% | 943 | $710.20 |
| 99407 | <1% | 380 | $414.58 | |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 280 | $243.24 |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNIEMAN, AMY (DIRECTOR OF CREDENTIALING)
| Provider | Location | Paid |
|---|---|---|
| Column Health, LLC | Lawrence, MA | $32.69M |
| Brightview LLC | Lynchburg, VA | $31.97M |
| Brightview LLC | Nicholasville, KY | $11.47M |
| Chesapeake Treatment Services LLC | Easton, MD | $5.20M |
| Chesapeake Treatment Services Ocean City LLC | Ocean City, MD | $4.74M |
| Brightview LLC | Lexington, KY | $2.06M |
| Brightview LLC | Cincinnati, OH | $1.13M |
| Brightview LLC | Paris, KY | $1.03M |
| Brightview LLC | Asheboro, NC | $597K |
| Brightview LLC | London, KY | $579K |
| Brightview LLC | Louisville, KY | $29K |
| Brightview LLC | Georgetown, KY | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.